AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 2:00 AM ET Oculis will host an in-person and virtual R&D Day at St. Regis New York on Tuesday, December 8, 2026, at 10:00 EST/16:00 CET. AI-generated summary · Source: company release
U.S. listed: $OCSBiotech · OphthalmologyExecution and funding risks

OCS Stock Hub: Oculis Holding News, Eye-Disease Pipeline and Clinical Data

Oculis’s Q3 update sets distinct clinical and funding tests. September cash, equivalents and deposits totaled CHF 210.291 million, with a company-stated US$252.0 million equivalent and runway into H2 2029. PREDICT-1 topline is expected around year-end 2026 and acute-MS privosegtor IND clearance in Q4. The November 3 ATM supplement provides up to US$125 million capacity, rather than completed fundraising. The financial note still describes Accure closing as pending. Financial statements. Company update. ATM supplement.

Last updated: November 9, 2026Market reference: November 3, 2026 completed U.S. regular-session close US$7.63Financial period: quarter and nine months ended September 30, 2026; IFRS in CHFUSD financial equivalents are company translations; U.S. security is an ordinary share
Full research report · PDF
Oculis research updated November 4, 2026
24 pages. All thirteen analytical chapters: post-DIAMOND scenarios, reporting and ordinary shares, privosegtor and ACUITY limits, PIONEER-1 and SPA, licaminlimab and PREDICT-1, retracted historical evidence, Accure and Novartis rights, Q3 and nine-month IFRS financials, cash and deposits, dilution, borrowing conditions, manufacturing and execution. Daily price and volume chart with SMA 50/200 on page 2 through November 3, dated historical financial analyses and eight complete FAQ answers. Personal use only: redistribution prohibited.
Get the report (PDF)
Company-guided clinical windows
Q4 2026 · acute-MS IND clearance; year-end · PREDICT-1 topline

Randomization of 176 PREDICT-1 patients is complete, with topline expected around year-end. Oculis expects privosegtor IND clearance for acute MS relapses in Q4. These are company forecasts and distinct regulatory steps, rather than completed approvals. Source.

R&D Day is scheduled for Tuesday, December 8, 2026 at 10:00 a.m. ET (16:00 CET) at the St. Regis New York, in person and virtually; announced on November 9, it is to cover licaminlimab and PREDICT-1, privosegtor’s PIONEER program and its planned development in acute MS relapse, with external ophthalmology and neurology experts. R&D Day announcement. The PIONEER-1 registry estimates primary completion December 2027 and study completion December 2028; these are study estimates rather than promised announcement days. Company schedule. PIONEER-1 registry.
Oculis Holding OCS daily stock chart
Daily chart $OCS. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

OCS stock at a glance

Close – November 3
US$7.63
Completed U.S. regular session; ordinary share
Price series in PDF, page 2
Cash and deposits
CHF 210.291M
September 30; company USD equivalent US$252.0M
SourceCompany USD equivalent
Q3 net loss
CHF 18.236M
Basic/diluted loss per share CHF 0.30
Source
9M operating cash use
CHF 54.531M
Derived Q3 use CHF 18.960M
SourceH1 comparison
9M operating loss
CHF 68.934M
Different from net loss CHF 57.058M
Source
Ordinary shares – September 30
61,919,609
Excludes 6,204,103 treasury shares
Source
ATM capacity – November 3
Up to US$125M
Available under new supplement; not cash already received
Source
Company runway
H2 2029
November 3 forecast; depends on operating plan
Source

Where Oculis Holding stands now

On November 2, 2026, Oculis announced Björn Tackenberg’s appointment as Chief Scientific Officer and said Aaron Tansy had recently joined as Vice President, Development Franchise Head, Neurology. Their roles support PIONEER and planned neurological development; appointments are distinct from clinical results. Source.

Q3 net loss was CHF 18.236 million, with operating loss CHF 23.638 million, R&D CHF 15.054 million and G&A CHF 8.591 million. Nine-month net loss improved to CHF 57.058 million despite operating loss widening to CHF 68.934 million. Warrant revaluation and exchange gains contributed to the finance result; they are different from product revenue or equivalent cash generation. Source.

September liquidity of CHF 210.291 million combines CHF 66.292 million cash and CHF 143.999 million short-term deposits. Nine-month operating cash use was CHF 54.531 million, and Q3 use CHF 18.960 million follows by subtracting H1 CHF 35.571 million. The company states US$252.0 million equivalent and runway into H2 2029. H1 comparison. Company conversion and forecast. Source.

The November 3 supplement provides up to US$125 million ATM capacity after giving effect to the amendment; prior sales are not subtracted again from that new capacity. The September outstanding count was 61,919,609 ordinary shares after excluding treasury stock. Accure maximum consideration includes conditional shares, and Note 4 says the transaction has not yet closed. ATM capacity. Source.

The constructive case

Resources support independent tests of selected-population dry-eye symptom relief and neuroprotection. Reproducible effects, disciplined development and workable manufacturing could strengthen the programs.

The cautious case

DIAMOND’s failed efficacy endpoints, small early neuroprotection evidence, diagnostic and manufacturing dependencies, ongoing cash use and future dilution remain material. Success in one program cannot establish success in the other.

Latest Oculis Holding news

Nov 9, 2026

Oculis to host in-person and virtual R&D Day: advancing a differentiated late-stage development pipeline

Oculis will host an in-person and virtual R&D Day at St. Regis New York on Tuesday, December 8, 2026, at 10:00 EST/16:00 CET. The event will cover Licaminlimab in dry eye disease, with topline results from the PREDICT-1 registrational trial anticipated around year-end, and Privosegtor across neuro-ophthalmology and neurology. Key opinion leaders and two recent hires, Chief Scientific Officer Prof. Björn Tackenberg and Franchise Head, Neurology Aaron Tansy, will participate.

Nov 3, 2026

Oculis amends Leerink sales agreement, raising at-the-market capacity to $125,000,000

On November 3, 2026, Oculis entered into Amendment No. 1 to its Amended and Restated Sales Agreement with Leerink Partners LLC. After the amendment, it can offer up to $125,000,000 of ordinary shares in at-the-market sales. The company had sold $61,323,500 of shares under the prior $100,000,000 agreement. Leerink Partners will receive commission of up to 3.0% of gross proceeds.

Nov 3, 2026

Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements

Oculis Holding AG published unaudited condensed consolidated interim financial statements as of September 30, 2026. The loss for the period was CHF 57,058 thousand for the nine months ended September 30, 2026, and CHF 18,236 thousand for the three months. Cash and cash equivalents were CHF 66,292 thousand and short-term financial assets were CHF 143,999 thousand as of September 30, 2026. The statements were approved for issuance by the Audit Committee on November 3, 2026.

Nov 3, 2026

Oculis reports Q3 2026 financial results and builds momentum toward pipeline catalysts

Oculis completed randomization in the PREDICT-1 registrational trial of Licaminlimab for TNFR1-mediated dry eye disease, with topline results anticipated around year-end 2026. IND clearance for Privosegtor in acute multiple sclerosis relapses is expected in Q4 2026. Cash, cash equivalents, and short-term investments were $252.0 million as of September 30, 2026, providing cash runway into 2H 2029. Net loss was CHF 57.1 million or $71.7 million for the nine months ended September 30, 2026. An R&D Day is scheduled for December 8, 2026.

Nov 2, 2026

Oculis appoints Bjorn Tackenberg as Chief Scientific Officer to advance neurology innovation

Oculis Holding AG appointed Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to lead its global integrated scientific strategy. He joins from Roche, where he served as Head of Integrative Neuroscience & Medical Practice, and previously was Head of the Center of Neuroimmunology at Marburg University from 2008 to 2019. The company also appointed Aaron Tansy, M.D., as Vice President, Development Franchise Head, Neurology. Initial priorities include advancing Privosegtor through the PIONEER registrational program and evaluating it in acute multiple sclerosis (MS) relapses.

Oct 29, 2026

Privosegtor presentations scheduled in early November

Oculis announced APOIS on November 1 and CNS Summit presentations on November 2–3 covering the PIONEER program and Phase 2 ACUITY evidence. These presentations are separate from the PREDICT-1 licaminlimab readout around year-end.

OCS stock catalysts and company milestones

  • Q4 2026: company expectation for acute-MS privosegtor IND clearance, rather than marketing approval.
  • Around year-end 2026: company guidance for PREDICT-1 topline after completed randomization.
  • Q4 2026: PIONEER-2 initiation planned in the MD&A; no initiation is inferred for PIONEER-3.
  • December 8, 2026, 10:00 a.m. ET: in-person and virtual R&D Day at the St. Regis New York on licaminlimab and privosegtor, a pipeline presentation rather than an earnings release or a clinical readout. Announcement.
  • December 2027/December 2028: PIONEER-1 primary/study completion estimates in the registry.
  • Accure: closing remains pending in the financial note approved November 3, with conditional cash/share consideration.

Clinical outcomes, IND steps, investor events and transaction closing have separate meanings and dates. Company outlook. PIONEER development plans. PIONEER-1 registry. Source.

Oculis pipeline: PREDICT-1, PIONEER-1 and distinct clinical evidence

The November 3 release reports all 176 PREDICT-1 patients randomized, about two-thirds carrying the relevant TNFR1 variant. The trial tests a dry-eye symptoms hypothesis in a selected population. The registry’s Day 29 genotype-specific primary endpoint and December 2026 completion estimate are different from an announced result. PREDICT-1 design. Source.

PIONEER-1 is the controlled registrational optic-neuritis study, with a primary LCVA responder endpoint and longer development timetable. The new ACUITY biomarker analyses support a hypothesis, rather than completed pivotal confirmation. SPA, Breakthrough Therapy and PRIME concern development interaction rather than approval. PIONEER-1 design. Source.

The prior DIAMOND trials missed their Week 52 visual-acuity primary and key secondary endpoints; anatomical observations did not reverse that result. Retracted historical licaminlimab pharmacogenomic evidence is discussed with its primary record and limitations in the PDF. Each remaining program must stand on its own controlled evidence. Source.

OCS financial record: CHF, IFRS and non-cash earnings effects

Financial statements use CHF, while U.S. ordinary shares trade in USD. The release’s US$252.0 million liquidity equivalent is the company’s September translation, not a current exchange-rate quote. Q3 operating expenses were CHF 23.645 million, including CHF 6.717 million share compensation; nine-month operating expenses were CHF 69.460 million, including CHF 18.361 million share compensation. Company translation. Source.

Nine-month warrant fair-value gain was CHF 7.273 million and exchange gain CHF 3.742 million, versus losses a year earlier. Operating cash use increased to CHF 54.531 million. Net-loss improvement therefore differs from better recurring operations. Warrant liability CHF 4.663 million is distinct from borrowed principal. Source.

Cash flows show CHF 54.531 million operating outflow, CHF 11.218 million investing outflow and CHF 47.557 million financing inflow before the separate exchange effect. Deposits are resources, not all immediately available cash; moving money between cash and deposits is different from clinical spending. Lease liabilities were CHF 2.786 million. Undrawn borrowing capacity and new ATM capacity are conditional future financing, not balances already received. Source.

Merlintrader Health Score · $OCS

3.10out of 5
Balance sheet and runway · 30%4.5

September 30, 2026 cash and short-term deposits totaled CHF 210.291 million, with CHF 54.531 million nine-month operating cash use. The company states US$252.0 million equivalent and runway into H2 2029. Undrawn debt capacity is conditional, and trial, transaction and launch spending can change funding needs.

Catalyst · 30%2.5

The November 3, 2026 update expects PREDICT-1 topline around year-end and acute-MS privosegtor IND clearance in Q4, with R&D Day on December 8 at 10:00 a.m. ET, as confirmed on November 9. These are company windows, not approvals or exact readout days. The longer PIONEER program and selected-population efficacy remain important uncertainties.

Dilution · 20%2.5

September 30, 2026 ordinary shares outstanding were 61,919,609 after treasury shares are excluded. The November 3 ATM supplement provides up to US$125 million capacity, rather than completed fundraising. Options, RSUs, warrants and conditional Accure share consideration can dilute participation; their terms and dates differ.

Liquidity · 10%2.5

The November 3, 2026 U.S. completed close was US$7.63, with 397,000 shares traded and twenty sessions averaging 200,505. Ordinary shares trade separately from the public warrants. Observed turnover does not prevent repricing around concentrated clinical and regulatory events.

Execution · 10%2.5

PREDICT-1 randomization is complete at 176 patients and PIONEER-1 is advancing, according to the November 3, 2026 update. Pivotal confirmation, recruitment, diagnostic and manufacturing requirements remain. DIAMOND missed its primary efficacy endpoints, and an Accure agreement is different from its completed asset closing.

Reassessed November 4, 2026; reviewed November 9, 2026 after the R&D Day announcement, which schedules a presentation rather than a result; scores unchanged. Weighted calculation: 4.5 x 30% + 2.5 x 30% + 2.5 x 20% + 2.5 x 10% + 2.5 x 10% = 3.10 / 5. Financial and operational robustness over twelve to eighteen months; not an investment recommendation or a price target.

Red flags

  • DIAMOND’s pivotal primary and key secondary efficacy endpoints failed.
  • Privosegtor early patient evidence is small and not a completed pivotal confirmation.
  • Biomarkers, anatomical outcomes and functional endpoints are different evidence.
  • Licaminlimab’s selected-population hypothesis requires its own result and potential diagnostic pathway.
  • Retracted historical evidence cannot serve as valid independent support.
  • Study-completion estimates, IND clearance and marketing approval are different milestones.
  • Manufacturing and commercial-scale requirements remain alongside clinical testing.
  • Net-loss improvement reflects substantial non-cash finance effects while operating use continues.
  • ATM capacity, awards, warrants and conditional Accure consideration create potential dilution.
  • Accure closing is pending in the financial note; maximum consideration is not all already paid or issued.
  • Undrawn loan capacity has timing, covenant and fee conditions.
  • Runway into H2 2029 is a company operating forecast.

OCS Stock FAQ: Oculis Questions Answered

What is the next catalyst for OCS stock?

As of November 3, 2026, Oculis expects PREDICT-1 licaminlimab topline around year-end 2026 and FDA IND clearance for privosegtor in acute multiple sclerosis relapses in Q4 2026. Its in-person and virtual R&D Day is scheduled for December 8 at 10:00 a.m. ET in New York (November 9 announcement). PREDICT-1 randomization is complete; the registry’s December 2026 study-completion estimate is not a fixed results-publication date. November 3 Q3 results. PREDICT-1 registry.

Is Oculis privosegtor FDA approved?

No. As of November 3, 2026, Oculis describes privosegtor as investigational, with no commercial approval in any country. Its May 7 announcement described an FDA Special Protocol Assessment agreement for the optic-neuritis registrational trial. That agreement concerns trial design and does not constitute acceptance or approval of a marketing application. Oculis investigational-drug status. May 7 protocol agreement.

How much cash does Oculis have and how long could it last?

Oculis held CHF 210.291 million in cash, equivalents and short-term deposits at September 30, 2026; its November 3 release states US$252.0 million equivalent and runway into H2 2029. Nine-month operating cash use was CHF 54.531 million. That forecast depends on planned spending and differs from the board’s at-least-twelve-month going-concern assessment. Loan capacity is undrawn and conditional, rather than cash already owned. Financial statements and cash flow. Company conversion and runway.

Could Oculis issue more shares?

Yes. Oculis’s November 3, 2026 supplement provides up to US$125 million ATM capacity after the amendment. September ordinary shares outstanding were 61,919,609, excluding treasury stock. Options, RSUs, warrants and potential Accure consideration of up to 2,050,000 shares can dilute holders. Accure includes conditional shares and its closing remains pending in the financial note, rather than all maximum shares already issued. New ATM capacity. Share count, instruments and transaction.

When does Oculis report its next earnings?

As of November 4, 2026, Oculis has not announced its next quarterly earnings date. It reported Q3 results November 3, with CHF 18.236 million net loss for the quarter and CHF 57.058 million over nine months. R&D Day on December 8 is a pipeline presentation rather than an earnings release. November 3 results and schedule. Company events.

What does Oculis do?

Oculis develops treatments for neuro-ophthalmic and eye diseases, as described in its November 3, 2026 update. Investigational privosegtor, formerly OCS-05, targets neuroprotection in optic neuropathies with planned acute-MS development. Licaminlimab, formerly OCS-02, is a topical anti-TNFα candidate for TNFR1-mediated dry-eye disease. These assets have different mechanisms, populations and clinical tests; neither is an approved commercial product. Company strategy and programs. Development and business.

Did Oculis OCS-01 succeed in the DIAMOND trials?

No. On May 29, 2026, Oculis reported that both pivotal DIAMOND studies missed their Week 52 primary visual-acuity endpoint and the key secondary endpoint of at least a 15-letter visual-acuity gain. Retinal-thickness improvements did not change those outcomes. Oculis said it did not plan an FDA filing for OCS-01 in diabetic macular edema. May 29 DIAMOND results.

Is Oculis OCS an ADS or an ordinary share?

OCS represents Oculis ordinary shares, according to its 2025 annual report. The ordinary shares trade on Nasdaq Global Market and Nasdaq Iceland Main Market. OCSAW is the separate public-warrant ticker; the ordinary shares and warrants are distinct securities. Form 20-F, listed securities.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $OCS or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Clinical-development companies carry efficacy, safety, regulatory, manufacturing and financing risks. Favorable exploratory data do not guarantee pivotal success or approval. Equity issuance can dilute holders, and investors can lose part or all of their capital. Readers remain responsible for their decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.